Recent whole-exome sequencing studies provided evidence of HER2 activation by somatic mutation, amplification, and human papilloma virus (HPV) integration in cervical cancer [12], warranting investigation of the effects of HER2 inhibitors. The gene discussed is ERBB2; the disease is cervical carcinoma.